Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
MATTHEW HAMILTON INGHAM
🇦🇺
Australia
Country
🇦🇺
Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News
Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
Phase 1
Withdrawn
Conditions
Liposarcoma
Malignant Peripheral Nerve Sheath Tumors
Alveolar Soft Part Sarcoma
Ewing Sarcoma
Sarcoma
Interventions
Drug: Selinexor
Drug: Ixazomib
Subscribe
First Posted Date
2019-03-19
Last Posted Date
2020-11-27
Lead Sponsor
Matthew Ingham
Registration Number
NCT03880123
Locations
🇺🇸
Columbia University Medical Center, New York, New York, United States
Subscribe
Prev
1
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy